EAACI Congress 2024
BackAsthma 1
Friday 31 May, 12:00 PM -
13:00 PM Valencia, Spain
Poster Zone
Thematic Poster Session
12:00
Baseline FeNO as a predictive marker of response to Dupilumab
12:00
Benralizumab effectiveness in severe eosinophilic asthma patients from Central Eastern Europe and Baltics: BREEZE study
12:00
Effects of dupilumab on quality of life and airflow obstruction in refractory type 2 high severe unified airways disease
12:00
Evaluation of remission of Severe Asthma treated with monoclonal antibodies according to different definitions: a single center cohort
12:00
Indirect case matched comparison of dupilumab versus benralizumab on mannitol airway hyperresponsiveness in type 2 high severe asthma
12:00
Infective asthma exacerbations in severe asthmatic patients receiving biological drugs
12:00
Long-term immune response accompanies clinical outcomes in severe asthmatics treated with anti-IL-5/IL-5R biologics
12:00
Predictors of Treatment Response to Biological Therapy in Patients with Severe Asthma: Insights from Induced Sputum Analysis
12:00
Real-Life effectiveness of a Cohort of Patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Concomitant Moderate Persistent Asthma Treated with Dupilumab
12:00
Real-life data analysis of severe asthma patients undergoing biologic therapy: OCS consumption and respiratory function evaluation
12:00
Real-world efficacy of dupilumab as a second-line treatment in severe asthma- data from a tertiary pulmonary centre
12:00
Toward Optimal disease control: impact of maintenance inhaler therapy and device transition in severe asthma patients undergoing monoclonal antibody treatment
